Published in AIDS Weekly and Law, March 8th, 2007
After the recent sudden halt of the Ushercell clinical trials, our management felt that this message should be imparted to shareholders at this time.
The cancelled trial status has not impacted the Company's existing sales or revenue, nor has it affected our daily business operations.
The state of our business operations remains strong. Sales and revenue have been growing in recent years. We have worked on reducing our operating expenses and increasing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly and Law
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.